| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/05/2004 | US20040023942 Novel, water-soluble porphyrin platinum compounds with high tumor selectivity and their use for the treatment of benign and malignant tumor diseases |
| 02/05/2004 | US20040023937 Anti-cancer formulation |
| 02/05/2004 | US20040023936 17 Beta-amino and hydroxylamino-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 02/05/2004 | US20040023934 Method of treating prostatic diseases using active vitamin D analogues |
| 02/05/2004 | US20040023933 Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-Xt-L-(W)p-NO2 wherein A contains the radical of a drug, Xt and W arc bivalent radicals, L, is a |
| 02/05/2004 | US20040023932 Imidazonaphthyridine and tetrahydroimidazonaphthyridine compounds induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the |
| 02/05/2004 | US20040023925 Method for enhancing the effectiveness of therapies of hyperproliferative diseases |
| 02/05/2004 | US20040023902 Delivery system contains a fusion protein having a target moiety and a nucleic acid binding moiety, and a nucleic acid sequence bound to the nucleic acid binding moiety of the fusion protein. The target moiety can be an antibody or a |
| 02/05/2004 | US20040023901 Novel nucleoside bases and phosphate moiety mimics optionally having sugar-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a |
| 02/05/2004 | US20040023891 Agents for neutron capture therapy |
| 02/05/2004 | US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively. |
| 02/05/2004 | US20040023881 Methods for the modulation of the growth of collateral arteries and/or other arteries from preexisting arteriolar connections |
| 02/05/2004 | US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2004 | US20040023877 Plasminogen fragments containing kringle region domains having anti-angiogenic activity and terned angiostatin protein. The plasminogen fragments of the present invention may be used for the treatment of angiogenesis-dependent diseases such as |
| 02/05/2004 | US20040023869 Interleukin-1 inhibitors in the treatment of diseases |
| 02/05/2004 | US20040023854 Adiponectin and uses thereof |
| 02/05/2004 | US20040023389 Plasmid coding proteins associated with immune response for immunotherapeutic treatment of cancer; gene therapy; anticarcinogenic agents |
| 02/05/2004 | US20040023339 Transgenic cell culture for preparing monoclonal antibodies for treatment and prevention of cancer |
| 02/05/2004 | US20040023337 IL-13 mutein proteins, antibodies, compositions, methods and uses |
| 02/05/2004 | US20040023335 IL-17 like molecules and uses thereof |
| 02/05/2004 | US20040023332 Genes of il-12p40 subunit mutated for improving the activity of il-12 and thereof for dna vaccine adjuvant |
| 02/05/2004 | US20040023307 DNA encoding a novel RG1 polypeptide |
| 02/05/2004 | US20040023278 Sialoadhesin family member-2 (SAF-2) |
| 02/05/2004 | US20040023267 Comprises nucleotide sequences coding cancer associated proteins (CAP) for diagnosis, prevention and treatment of tumors |
| 02/05/2004 | US20040023240 Combinatorial production of nucleotide and nucleoside(xitp)analogues |
| 02/05/2004 | US20040023204 Peptides which enhance transport across tissues and methods of identifying and using the same |
| 02/05/2004 | US20040022870 Immunogenic TLP composition |
| 02/05/2004 | US20040022869 Containing microtubule stabilizing agents and one or more heat shock protein (HSP)-inducing agents; treating a proliferative disorder, an infectious disease, a cardiovascular disease, an autoimmune disorder, or an inflammatory disorder |
| 02/05/2004 | US20040022791 Use of the heavy chain of an antibody, of a functional derivative, or of a fragment thereof, comprising a CDR3 region for jointly inhibiting fibrinogen binding to platelets and vitronectin binding to endothelial cells |
| 02/05/2004 | US20040022785 Expression of herstatin, an alternative HER-2/neu product, in cells that express either p185HER-2 or the EGF receptor inhibits receptor activity and cell growth |
| 02/05/2004 | US20040022781 Proteins and nucleic acids encoding same |
| 02/05/2004 | US20040022774 Fibrocyte-based vaccine formulations |
| 02/05/2004 | US20040022770 Eliciting an immune response against prostate specific antigen (PSA) in a mammal by administering an effective amount of a recombinant bacille Calmette-Guerin (rBCG) strain expressing PSA |
| 02/05/2004 | US20040022760 Administering Flt3-ligand to a subject; optionally administering an auxiliary molecule; administering a vaccine to the subject, wherein the vaccine comprises an antigen and an adjuvant |
| 02/05/2004 | US20040022734 For therapy of cancer, of fluorescent imaging and optoelectronics |
| 02/05/2004 | US20040022727 For therapy of proliferative diseases |
| 02/05/2004 | DE10233632A1 Formulierungen von Phenylalanin-Derivaten Formulations of phenylalanine derivatives |
| 02/05/2004 | DE10232094A1 5-Thiaepothilone und 15-disubstituierte Epothilone 5-Thiaepothilone and 15-disubstituted epothilones |
| 02/05/2004 | DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/05/2004 | DE10230917A1 Fredericamycin-Derivate Fredericamycin derivatives |
| 02/05/2004 | DE10229456A1 Treatment of skin tumors and warts, by local application of preparations containing dopamine receptor agonists, especially bromocriptine |
| 02/05/2004 | DE10148618A1 Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel Substituted N- (1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their preparation and use as medicaments |
| 02/05/2004 | CA2802205A1 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 02/05/2004 | CA2495167A1 Structural carotenoid analogs for the inhibition and amelioration of disease |
| 02/05/2004 | CA2494532A1 Total synthesis of myriaporones |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494262A1 Polymorphisms for predicting disease and treatment outcome |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493878A1 Parenteral formulations containing a rapamycin hydroxyester |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493701A1 Isothiazole derivatives useful as anticancer agents |
| 02/05/2004 | CA2493639A1 Persulfated oligosaccharide acting on selectins and chemokine |
| 02/05/2004 | CA2493590A1 Auto-stimulating cells and method for making and using the same |
| 02/05/2004 | CA2493172A1 Method of treating tumors |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2492447A1 Taci antibodies and uses thereof |
| 02/05/2004 | CA2401567A1 Methods of preventing the inhibition of apoptosis and treating inflammatory conditions |
| 02/04/2004 | EP1386933A1 Cytokine antagonists and agonists |
| 02/04/2004 | EP1386932A1 Improved humanized immunoglobulins |
| 02/04/2004 | EP1386923A1 Novel adenine derivatives |
| 02/04/2004 | EP1386912A1 Cyclic amidine derivative |
| 02/04/2004 | EP1386639A1 Use of 78 genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer |
| 02/04/2004 | EP1386615A1 EG-VEGF/Prokineticin 2 receptor antagonists |
| 02/04/2004 | EP1386279A2 Method for inhibiting metap2 |
| 02/04/2004 | EP1386166A2 Anti-epileptogenic agents |
| 02/04/2004 | EP1386162A2 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors |
| 02/04/2004 | EP1386156A2 Individualization of therapy with antineoplastic agents |
| 02/04/2004 | EP1386152A2 Production of polyclonal monospecific antibodies against upar variants del4, del5 and del4+5, and the use thereof for diagnostic and therapeutical purposes |
| 02/04/2004 | EP1385993A2 Method of detecting and treating tuberous sclerosis complex associated disorders |
| 02/04/2004 | EP1385992A2 Cancer associated protein kinases and their uses |
| 02/04/2004 | EP1385980A2 Yeast strains autonomously producing steroids |
| 02/04/2004 | EP1385977A2 Secreted proteins |
| 02/04/2004 | EP1385959A2 Method of producing recombinant antibodies against tumours |
| 02/04/2004 | EP1385954A2 Proteins associated with cell growth, differentiation, and death |
| 02/04/2004 | EP1385953A2 Proteins and nucleic acids encoding same |
| 02/04/2004 | EP1385952A2 Methods of inhibiting expression of a target gene in mammalian cells |
| 02/04/2004 | EP1385937A1 Delivery of polynucleotide agents to the central nervous sysstem |
| 02/04/2004 | EP1385934A2 Pufa polyketide synthase systems and uses thereof |
| 02/04/2004 | EP1385883A2 Transmembrane proteins |
| 02/04/2004 | EP1385882A2 Peptides and related molecules that bind to tall-1 |
| 02/04/2004 | EP1385879A1 Reproductive cancer diagnosis and therapy |
| 02/04/2004 | EP1385874A1 Alpha conotoxin peptides with analgesic properties |
| 02/04/2004 | EP1385872A1 Inhibitors of receptor activator of nf-kappa b and uses thereof |
| 02/04/2004 | EP1385864A1 Vascular endothelial growth factor 2 |
| 02/04/2004 | EP1385861A2 Compositions and methods relating to lung specific genes and proteins |
| 02/04/2004 | EP1385852A1 Compounds and methods for inhibiting mrp1 |
| 02/04/2004 | EP1385846A2 Synthesis of pancratistatin prodrugs |
| 02/04/2004 | EP1385845A1 N-aroyl cyclic amines |
| 02/04/2004 | EP1385837A1 Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors |
| 02/04/2004 | EP1385836A2 Aromatic sulfone hydroxamates and their use as protease inhibitors |
| 02/04/2004 | EP1385835A1 Benzoxazinone derivatives for use in the treatment of angiogenesis |
| 02/04/2004 | EP1385833A1 Triazinyl amide derivatives as angiogenesis inhibitors |
| 02/04/2004 | EP1385818A2 Biurethane derivatives |
| 02/04/2004 | EP1385551A1 Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil |
| 02/04/2004 | EP1385547A1 Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancer |
| 02/04/2004 | EP1385546A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents |
| 02/04/2004 | EP1385542A2 Treatment and prevention of ebv infection and ebv-associated disorders |
| 02/04/2004 | EP1385539A1 Cancer metastasis interfering vaccine |
| 02/04/2004 | EP1385538A2 Chimeric vaccines |